share_log

This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

這位分析師看好Snap股票;以下是週三的五個最佳升級
Benzinga ·  10/23 21:05

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

華爾街頂級分析師改變了對這些頂級公司的展望。如需查看包括升級和降級在內的所有分析師評級變化的完整視圖,請參閱我們的分析師評級頁面。

  • Piper Sandler analyst Alexander Goldfarb upgraded the rating for BXP, Inc. (NYSE:BXP) from Neutral to Overweight and raised the price target from $78 to $105. BXP shares closed at $86.82 on Tuesday. See how other analysts view this stock.
  • JMP Securities analyst Andrew Boone upgraded Snap Inc. (NYSE:SNAP) from Market Perform to Market Outperform and announced a $17 price target. Snap shares closed at $9.98 on Tuesday. See how other analysts view this stock.
  • Argus Research analyst David Coleman upgraded the rating for Alcoa Corporation (NYSE:AA) from Hold to Buy. Alcoa shares closed at $42.02 on Tuesday. See how other analysts view this stock.
  • UBS analyst Damian Karas upgraded A. O. Smith Corporation (NYSE:AOS) from Sell to Neutral and raised the price target from $75 to $80. A.O. Smith shares closed at $78.21 on Tuesday. See how other analysts view this stock.
  • Baird analyst Eric Coldwell upgraded the rating for Quest Diagnostics Incorporated (NYSE:DGX) from Neutral to Outperform and boosted the price target from $157 to $182. Quest Diagnostics shares closed at $157.47 on Tuesday. See how other analysts view this stock.
  • 派傑投資分析師亞歷山大·戈德法博將BXP公司(紐交所:BXP)的評級由中立調升爲超重,並將目標股價從78美元提高至105美元。週二,BXP股價收於86.82美元。查看其他分析師對這支股票的看法。
  • JMP證券分析師安德魯·布恩將snap inc(紐交所:SNAP)的評級從市場表現升級至市場表現優異,並宣佈17美元的價格目標。週二,snap inc股價收於9.98美元。查看其他分析師對這支股票的看法。
  • 雅運股份研究分析師大衛·科爾曼將美國鋁業公司(紐交所:AA)的評級由持有調升爲買入。週二,美國鋁業公司股價收於42.02美元。查看其他分析師對這支股票的看法。
  • 瑞銀分析師達米安·卡拉斯將a.o.史密斯公司(紐交所:AOS)的評級由賣出調升爲中立,並將目標股價從75美元提高至80美元。週二,a.o.史密斯公司股價收於78.21美元。查看其他分析師對這支股票的看法。
  • Baird分析師埃裏克·科爾德韋爾將奎斯特診療公司(紐交所:DGX)的評級由中立調升爲超買,並將目標股價從157美元提高至182美元。週二,奎斯特診療公司股價收於157.47美元。查看其他分析師對這支股票的看法。

Read More:

閱讀更多:

  • Dow Edges Lower As Investors Watch Earnings Reports With Caution: Fear Index Remains In 'Greed' Zone
  • 道瓊斯指數小幅下跌,投資者謹慎關注業績:恐懼指數仍處於'貪婪'區域

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論